Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
Line 41: | Line 40: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* 60 percent of squamous cell carcinomas occur at the site of a previous actinic keratosis | * 60 percent of squamous cell carcinomas occur at the site of a previous actinic keratosis | ||
Line 59: | Line 57: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule | | style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule | ||
|- | |- | ||
Line 76: | Line 73: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth) | | style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth) | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Two-thirds arise in normal skin, the rest in existing moles | * Two-thirds arise in normal skin, the rest in existing moles | ||
Line 95: | Line 91: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Do not make melanin, so lesions are not pigmented | * Do not make melanin, so lesions are not pigmented | ||
Line 114: | Line 109: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 133: | Line 127: | ||
* large, hyperchromatic, oval nuclei and little cytoplasm | * large, hyperchromatic, oval nuclei and little cytoplasm | ||
* well differentiated and cells appear histologically similar to basal cells of the epidermis | * well differentiated and cells appear histologically similar to basal cells of the epidermis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 150: | Line 143: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 158: | Line 150: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Other sites lungs, liver, brain, skin, or bone. | | style="background: #F5F5F5; padding: 5px;" |Other sites lungs, liver, brain, skin, or bone. | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 171: | Line 162: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign Skin Lesions''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign Skin Lesions''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 192: | Line 182: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Yellow-nodule | | style="background: #F5F5F5; padding: 5px;" |Yellow-nodule | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 206: | Line 195: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Rhabdomyosarcoma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Rhabdomyosarcoma''' | ||
| style="background: #F5F5F5; padding: 5px;" |Bulging of the eye or a swollen eyelid | | style="background: #F5F5F5; padding: 5px;" |Bulging of the eye or a swollen eyelid | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 235: | Line 223: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 241: | Line 228: | ||
| style="background: #F5F5F5; padding: 5px;" |Hard lesion | | style="background: #F5F5F5; padding: 5px;" |Hard lesion | ||
| style="background: #F5F5F5; padding: 5px;" |Itchy lumps | | style="background: #F5F5F5; padding: 5px;" |Itchy lumps | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 269: | Line 255: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease | | style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease | ||
| style="background: #F5F5F5; padding: 5px;" |chronic | | style="background: #F5F5F5; padding: 5px;" |chronic | ||
|- | |- | ||
Line 282: | Line 267: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
Line 294: | Line 278: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Verrucous lesion | | style="background: #F5F5F5; padding: 5px;" |Verrucous lesion | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 313: | Line 296: | ||
| style="background: #F5F5F5; padding: 5px;" |Red, dome-shaped | | style="background: #F5F5F5; padding: 5px;" |Red, dome-shaped | ||
| style="background: #F5F5F5; padding: 5px;" |Friable papule with a collarette of scale | | style="background: #F5F5F5; padding: 5px;" |Friable papule with a collarette of scale | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 328: | Line 310: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |multiple, red- to brown-colored, small papules that | | style="background: #F5F5F5; padding: 5px;" |multiple, red- to brown-colored, small papules that | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 348: | Line 329: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Coin shaped spots | | style="background: #F5F5F5; padding: 5px;" |Coin shaped spots | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 365: | Line 345: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Thick, white, silvery, or red patches of skin | | style="background: #F5F5F5; padding: 5px;" |Thick, white, silvery, or red patches of skin | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 383: | Line 362: | ||
| style="background: #F5F5F5; padding: 5px;" |Purulent ulcer | | style="background: #F5F5F5; padding: 5px;" |Purulent ulcer | ||
| style="background: #F5F5F5; padding: 5px;" |Ragged and violaceous border | | style="background: #F5F5F5; padding: 5px;" |Ragged and violaceous border | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 395: | Line 373: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Venous stasis ulcers''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Venous stasis ulcers''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 412: | Line 389: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Traumatic ulcers''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Traumatic ulcers''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 433: | Line 409: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Red scaly patch | | style="background: #F5F5F5; padding: 5px;" |Red scaly patch | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 454: | Line 429: | ||
Yellowish, soft, small papules on the face | Yellowish, soft, small papules on the face | ||
| style="background: #F5F5F5; padding: 5px;" |Usually on the nose, cheeks, and forehead | | style="background: #F5F5F5; padding: 5px;" |Usually on the nose, cheeks, and forehead | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 469: | Line 443: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Red rash | | style="background: #F5F5F5; padding: 5px;" |Red rash | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 486: | Line 459: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Red rash | | style="background: #F5F5F5; padding: 5px;" |Red rash | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 503: | Line 475: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Erythematous, dome-shaped papule | | style="background: #F5F5F5; padding: 5px;" |Erythematous, dome-shaped papule | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 516: | Line 487: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nevus''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nevus''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 533: | Line 503: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Chemical Burns''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Chemical Burns''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 563: | Line 532: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue | | style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue | ||
| style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor | | style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign hereditary intraepithelial dyskeratosis''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign hereditary intraepithelial dyskeratosis''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 585: | Line 552: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''primary acquired melanosis''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''primary acquired melanosis''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 615: | Line 581: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements | | style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements | ||
| style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism | | style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism | ||
Line 624: | Line 589: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Inflamed and hyperpigmented | | style="background: #F5F5F5; padding: 5px;" |Inflamed and hyperpigmented | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 642: | Line 606: | ||
| style="background: #F5F5F5; padding: 5px;" |Reddened, yellowish-tan color of lesions | | style="background: #F5F5F5; padding: 5px;" |Reddened, yellowish-tan color of lesions | ||
| style="background: #F5F5F5; padding: 5px;" |Slightly raised bumps | | style="background: #F5F5F5; padding: 5px;" |Slightly raised bumps | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 654: | Line 617: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous fungal infections''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous fungal infections''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 671: | Line 633: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Desmoplastic trichoepithelioma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Desmoplastic trichoepithelioma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 688: | Line 649: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Adnexal carcinoma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Adnexal carcinoma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 705: | Line 665: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 722: | Line 681: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Darier disease''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Darier disease''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 739: | Line 697: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous T-cell lymphoma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous T-cell lymphoma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 763: | Line 720: | ||
| style="background: #F5F5F5; padding: 5px;" |Rolled or everted wound margins | | style="background: #F5F5F5; padding: 5px;" |Rolled or everted wound margins | ||
| style="background: #F5F5F5; padding: 5px;" |Bleeding on touch | | style="background: #F5F5F5; padding: 5px;" |Bleeding on touch | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 782: | Line 738: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Increased size | | style="background: #F5F5F5; padding: 5px;" |Increased size | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 792: | Line 747: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Anogenital''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Anogenital''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 816: | Line 770: | ||
| style="background: #F5F5F5; padding: 5px;" |Dome-shaped or crateriform nodules with a central keratotic core | | style="background: #F5F5F5; padding: 5px;" |Dome-shaped or crateriform nodules with a central keratotic core | ||
| style="background: #F5F5F5; padding: 5px;" |Increased size | | style="background: #F5F5F5; padding: 5px;" |Increased size | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 17:31, 14 February 2019
Diseases | Clinical manifestations | Para-clinical findings | Additional findings | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||
Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Lab 1 | Lab 2 | Lab 3 | Imaging 1 | Imaging 2 | Imaging 3 | |||
Cutaneous squamous cell carcinoma | Pain | Erythema | Indurated | Hyperkeratotic | Increased size |
| ||||||||
Merkel cell carcinoma | Starts on areas of skin exposed to the sun | Single pink, red, or purple shiny bump | Painless | Blue-red, dome-shaped nodule | ||||||||||
Nodular malignant melanoma | Lump that has been rapidly growing over the past weeks | Cells proliferate downwards through the skin (vertical growth) |
| |||||||||||
Amelanotic melanoma | Color usually pink, purple or normal skin color | Usually have an asymmetrical shape with an irregular border | Red, nonspecific lesion with slightly elevated borders |
| ||||||||||
Basal cell carcinoma | Coarse scale lesion | |||||||||||||
Superficial basal cell carcinoma | Scaly patch | Erythematous lesion |
|
|||||||||||
Nodular basal cell carcinoma | Pearly papule with telangiectasias | |||||||||||||
Cutaneous metastases of internal malignancy | Other sites lungs, liver, brain, skin, or bone. | The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes; | ||||||||||||
Benign Skin Lesions | ||||||||||||||
Sebaceous cell carcinoma | Yellow-nodule | Suspected due to evidence of eyelash loss | ||||||||||||
Rhabdomyosarcoma | Bulging of the eye or a swollen eyelid | Develops in skeletal muscles usually | ||||||||||||
Actinic keratoses | Pain | Hyperkeratosis | Erythema | less pigmentation, and tend to be somewhat smaller in size. | ||||||||||
Prurigo nodules | Hard lesion | Itchy lumps | ||||||||||||
Paget disease | Eczema-like rash of the skin | Around the genital regions of males and females. | Similar to mammary paget disease | chronic | ||||||||||
Inflamed seborrheic keratosis | Waxy, "stuck on," often hyperkeratotic appearance | |||||||||||||
Viral warts | Verrucous lesion | Caused by HPV | ||||||||||||
Pyogenic granuloma | Rapidly growing | Red, dome-shaped | Friable papule with a collarette of scale | |||||||||||
Bowenoid papulosis | multiple, red- to brown-colored, small papules that |
| ||||||||||||
Nummular eczema | Itchy lesions | Coin shaped spots | Chronic condition | |||||||||||
Psoriasis | Flaking, inflammation | Thick, white, silvery, or red patches of skin | Chronic condition | |||||||||||
Pyoderma gangrenosum | Purulent ulcer | Ragged and violaceous border | ||||||||||||
Venous stasis ulcers | ||||||||||||||
Traumatic ulcers | ||||||||||||||
Bowen Disease | Red scaly patch | Very early form of skin cancer that is very treatable
referred to as squamous cell carcinoma insitu | ||||||||||||
Sebaceous Hyperplasia | Lesions can be single or multiple lesions |
Yellowish, soft, small papules on the face |
Usually on the nose, cheeks, and forehead | |||||||||||
Allergic Contact Dermatitis | Itchy rash | Red rash | Not contagious | |||||||||||
Atopic Dermatitis | Itchy rash | Fever | Red rash | Chronic and sometimes accompanied by asthma | ||||||||||
Atypical Fibroxanthoma | Erythematous, dome-shaped papule | |||||||||||||
Nevus | ||||||||||||||
Chemical Burns | ||||||||||||||
Limbal Dermoid | Contains choristomatous tissue | Benign congenital tumor | ||||||||||||
Benign hereditary intraepithelial dyskeratosis | Rare autosomal-dominant disorder of the conjunctiva and oral mucosa | |||||||||||||
primary acquired melanosis | ||||||||||||||
Fibrous xanthoma | Containing fibromatous elements | Arises due to disturbed systemic lipid metabolism | ||||||||||||
Inflamed seborrheic keratosis | Inflamed and hyperpigmented | |||||||||||||
Juvenile xanthogranuloma | Reddened, yellowish-tan color of lesions | Slightly raised bumps | Typically | |||||||||||
Cutaneous fungal infections | ||||||||||||||
Desmoplastic trichoepithelioma | ||||||||||||||
Adnexal carcinoma | Very rare | |||||||||||||
Keratoacanthoma | ||||||||||||||
Darier disease | Keratosis follicularis | |||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides | |||||||||||||
Marjolin's ulcer | Lesions in sites of chronic wounds and scars | Excessive granulation tissue, | Rolled or everted wound margins | Bleeding on touch |
| |||||||||
Epithelioma cuniculatum | Increased size | Verrucous carcinoma on the plantar foot | ||||||||||||
Anogenital | also known as giant condyloma acuminatum of Buschke-Loewenstein | |||||||||||||
Keratoacanthoma | Found on actinically damaged skin | Rapid initial growth | Dome-shaped or crateriform nodules with a central keratotic core | Increased size | keratocytic epithelial tumors |